Health & Wellness

Press Releases

Atlantic Health System Cancer Care First in World to Begin Clinical Trial of Novel Virus-Based Immunotherapy for Late-Stage Melanoma; First Patient Enrolled

42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg
42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg

Dr. Eric Whitman Leads Study of Experimental Drug That Uses Cold Virus to Disable Cancer Cells in Patients Who Have Not Responded to Other Treatments

MORRISTOWN, NJ -  Atlantic Health System Cancer Care is the first oncology institution in the world to sign on to, and to enroll the first patient in, a multicenter Phase IIa clinical trial of OBP-301 (Telomelysin®), a virus-based immunotherapy for late-stage melanoma that has not responded to other treatments. 

This leading-edge experimental therapy, which is under development by Japanese biotechnology company Oncolys BioPharma, uses the common cold virus to modify a gene that can selectively replicate in, and destroy, cancer cells. The study protocol was approved by the U.S. Food and Drug Administration (FDA) in June.

Sign Up for E-News

The clinical trial is being led locally by Eric D. Whitman, MD, FACS, medical director of Atlantic Health System Cancer Care and director of the Carol G. Simon Cancer Center’s Atlantic Melanoma Center at Morristown Medical Center and Overlook Medical Center.

“This targeted immunotherapy holds great promise for improving survival rates in patients with unresectable and metastatic melanoma,” said Dr. Whitman.  “We are proud to have been chosen as the first site for this leading edge clinical trial, and happy to be able to offer a wide range of the latest established and experimental treatments to our patients.”

Melanoma, the most serious form of skin cancer, affects more than 50,000 people each year. Although the chances of having melanoma increase with age, the number of cases among young adults is rising every year. Melanoma can have serious health consequences and may even be fatal.

The OBP-301 trial is a multicenter, Phase IIa study to evaluate how melanoma tumors respond to injection of this drug in patients with Stage III and Stage IV melanoma -- that is, to determine how much the drug shrinks or destroys tumors after it is injected into them.  The study, which will also look at potential side effects, is “open label,” meaning that all participants in the study will receive OBP-301. 

OBP-301 is a type of virus known as an adenovirus. Adenoviruses are common in nature and when they multiply in normal human cells they may cause infections that result in symptoms like those of the common cold or the flu.  OBP-301 has been genetically changed from the original virus to reproduce in target cancer cells that are emitting a certain signal. As a result of this reproduction, OBP-301 is believed to burst and kill tumor cells.

Study participants will receive multiple injections into their tumors over a period of several weeks.  Blood tests will be done to evaluate the level of virus in patients’ systems, and for immune response monitoring. Dr. Whitman and colleagues will also evaluate how long it takes to get a response and how long responses last, as well as overall survival and progression-free survival rates.

In preclinical studies, Oncolys demonstrated OBP-301’s anti-tumor activity in various types of cancer cells.  A Phase I clinical trial in the U.S. demonstrated the drug’s safety, and showed that it shrank tumors in a majority of study participants, who had a variety of solid tumors.  Additional studies of the drug have been completed, or are underway, in Japan, Korea and Taiwan.

The Atlantic Melanoma Center, a clinical and research center of excellence, is an internationally-recognized program. The center’s multidisciplinary approach-- combining the expertise of board-certified surgeons, medical oncologists, pathologists, radiation oncologists and nurses – treats all forms of melanoma, including those in the skin, mucous membranes and eyes.  Patients receive the latest medical treatments, and when needed, melanoma surgery is also available. 

For more information on the OBP-301 clinical trial or other studies, please call the Atlantic Melanoma Center at 973-971-7111.  

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Basking Ridge

Sleep out at Covenant House

June 18, 2018

I can enjoy the same movies over and over like it were the first time to see them.  My kids roll their eyes at this.  Well, many unimaginable things happen as you become a certain age, and you tend to learn to accept those things graciously as gift.   But I remember the movie “The Blind Side.”  Until I saw that movie, I didn’t know homeless children ...

Upcoming Events

Mon, June 25, 9:00 AM

Madison

Kids' Critter Camp

Education

Mon, June 25, 9:00 AM

The Wayrick Gallery, Scherman Hoffman Wildlife Sanctuary, Bernardsville

NJ Audubon: NJ Audubon Photography Instructors’ ...

Arts & Entertainment Green

Tue, June 26, 9:00 AM

The Wayrick Gallery, Scherman Hoffman Wildlife Sanctuary, Bernardsville

NJ Audubon: NJ Audubon Photography Instructors’ ...

Arts & Entertainment Green

Horse Care Workshops at Lord Stirling Stable Start June 23

June 17, 2018

BASKING RIDGE, N.J. — Somerset County Park Commission Lord Stirling Stable is offering Horse Care Workshop 101 for adults and youth seeking to gain experience and confidence around horses through a combination of non-riding activities and hands-on practice.

Horse Care Workshop 101 will be held at Lord Stirling Stable, 256 South Maple Avenue in Basking Ridge, NJ beginning Saturday June ...

AtlantiCast

AtlantiCast Episode 17

On this week’s AtlantiCast, it’s National Men’s Health Month, so check out important health tips for you or the men in your life, learn about groundbreaking research into breast cancer treatment that could mean an end to chemotherapy for some patients, meet a local sports hero who’s living his baseball dreams thanks to Goryeb Children’s Hospital and much ...